Standard BioTools Inc.
LAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.50 | -0.12 | 0.16 | -0.19 |
| FCF Yield | -4.64% | -4.95% | -8.65% | -2.66% |
| EV / EBITDA | -12.00 | -19.99 | -13.14 | -17.48 |
| Quality | ||||
| ROIC | -7.82% | -5.30% | -6.12% | -5.92% |
| Gross Margin | 48.51% | 48.84% | 48.39% | 46.89% |
| Cash Conversion Ratio | 0.64 | 0.62 | 1.16 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.00% | 13.51% | 17.08% | 17.70% |
| Free Cash Flow Growth | -2.36% | 36.17% | -102.61% | 42.10% |
| Safety | ||||
| Net Debt / EBITDA | 3.10 | 7.99 | 5.42 | 4.48 |
| Interest Coverage | 3,293.80 | -2,855.22 | -16,485.00 | -9.90 |
| Efficiency | ||||
| Inventory Turnover | 0.40 | 0.46 | 0.50 | 0.61 |
| Cash Conversion Cycle | 230.36 | 196.56 | 208.00 | 167.95 |